Profile data is unavailable for this security.
About the company
Cantargia AB is a Sweden-based company engaged in development of antibody therapeutics for the treatment of leukemia. The Company is engaged in the development of a therapy for the treatment of cancer by targeting a cell-surface receptor on malignant stem cells, through the development of antibody therapeutics for eradication of malignant stem cells. Cantargia AB uses the Interleukin-1 receptor accessory protein (IL1RAP), as the target for development of a novel antibody-based therapy for leukemia.
- Revenue in SEK (TTM)308.69m
- Net income in SEK139.93m
- Incorporated2009
- Employees23.00
- LocationCantargia ABScheelevagen 27LUND 223 63SwedenSWE
- Phone+46 462756260
- Websitehttps://cantargia.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lytix Biopharma AS | 351.04k | -68.18m | 695.16m | 6.00 | -- | 8.29 | -- | 1,980.30 | -1.08 | -1.08 | 0.0055 | 1.15 | 0.005 | -- | 0.0579 | 62,833.33 | -96.51 | -61.17 | -123.25 | -71.49 | -- | -- | -19,422.02 | -722.29 | -- | -- | 0.0301 | -- | 178.98 | 104.67 | -7.24 | -- | -- | -- |
| Oncopeptides AB | 62.58m | -267.84m | 716.23m | 75.00 | -- | 109.40 | -- | 11.45 | -1.20 | -1.20 | 0.2798 | 0.0253 | 0.2359 | 0.2049 | 1.79 | 782,225.00 | -100.98 | -148.24 | -125.09 | -215.27 | 97.88 | -- | -428.01 | -2,013.60 | 3.27 | -12.10 | 0.9507 | -- | -10.14 | -- | -14.25 | -- | -7.14 | -- |
| Hamlet BioPharma AB | 0.00 | -56.55m | 728.54m | 6.00 | -- | 18.07 | -- | -- | -0.3157 | -0.3157 | 0.00 | 0.2927 | 0.00 | -- | -- | 0.00 | -95.68 | -78.53 | -104.48 | -91.76 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -30.70 | -- | -- | -- |
| Nanoform Finland Oyj | 31.51m | -232.16m | 774.62m | 173.00 | -- | 1.63 | -- | 24.58 | -0.2613 | -0.2613 | 0.0354 | 0.5203 | 0.0442 | 80.07 | 9.22 | 16,328.73 | -32.55 | -26.72 | -36.27 | -29.06 | -441.87 | -539.46 | -736.69 | -918.61 | 4.30 | -- | 0.1281 | -- | 8.22 | 124.15 | -12.87 | -- | -1.62 | -- |
| Nykode Therapeutics ASA | 60.84m | -98.85m | 904.69m | 62.00 | -- | 1.01 | -- | 14.87 | -0.3148 | -0.3148 | 0.1974 | 2.93 | 0.0494 | -- | 1.91 | 470,088.80 | -8.03 | 2.32 | -8.66 | 2.60 | -- | -- | -162.46 | 8.51 | -- | -- | 0.0284 | -- | -32.73 | -- | -10.43 | -- | -1.35 | -- |
| XSpray Pharma AB (publ) | 0.00 | -216.42m | 968.42m | 26.00 | -- | 1.51 | -- | -- | -5.96 | -5.96 | 0.00 | 15.37 | 0.00 | -- | -- | 0.00 | -29.09 | -23.48 | -30.93 | -25.08 | -- | -- | -- | -- | 5.93 | -18.44 | 0.1883 | -- | -- | -- | -58.92 | -- | -14.46 | -- |
| Curasight A/S | -63.78m | -68.87m | 1.07bn | 4.00 | -- | 43.06 | -- | -- | -1.13 | -1.13 | -1.07 | 0.3809 | -1.52 | -- | -- | -11,171,250.00 | -163.63 | -37.34 | -313.58 | -40.89 | -- | -- | -- | -- | -- | -16.54 | 0.00 | -- | -27.21 | -- | -40.76 | -- | -- | -- |
| Cantargia AB | 308.69m | 139.93m | 1.32bn | 23.00 | 10.46 | 4.43 | 9.19 | 4.27 | 0.5068 | 0.5068 | 1.33 | 1.20 | 1.41 | -- | 164.02 | 14,031,360.00 | 63.91 | -56.56 | 80.65 | -63.93 | -- | -- | 45.33 | -- | -- | 76.55 | 0.00 | -- | -- | -- | 42.27 | -- | -- | -- |
| Nightingale Health Oyj | 50.04m | -196.84m | 1.42bn | 100.00 | -- | 1.46 | -- | 28.44 | -0.3052 | -0.3052 | 0.0778 | 1.10 | 0.0568 | 0.9444 | 2.79 | 46,930.00 | -22.33 | -15.66 | -24.26 | -16.95 | 75.39 | 75.21 | -393.39 | -447.17 | 8.52 | -- | 0.0511 | -- | 7.69 | 21.38 | -5.71 | -- | -12.69 | -- |
| Solar Foods Oyj | 203.76k | -113.72m | 1.48bn | 57.00 | -- | 6.52 | -- | 7,255.91 | -0.433 | -0.433 | 0.0008 | 0.7115 | 0.0004 | -- | 0.0037 | 455.00 | -22.45 | -- | -27.05 | -- | 25,931.57 | -- | -55,808.37 | -- | -- | -7.03 | 0.5092 | -- | 275.15 | -- | -22.57 | -- | -- | -- |
| Intellego Technologies AB | 770.81m | 294.66m | 1.55bn | 65.00 | 4.75 | 2.33 | 4.81 | 2.01 | 9.81 | 9.81 | 25.91 | 20.01 | 1.28 | 10.59 | 2.32 | 12,432,400.00 | 49.11 | 17.13 | 61.64 | 23.87 | 70.97 | 58.82 | 38.23 | 21.32 | 4.11 | 5.35 | 0.0617 | -- | 42.25 | 222.71 | 14.78 | -- | -- | -- |
| Thor Medical ASA | 93.11k | -54.85m | 1.57bn | 13.00 | -- | 3.50 | -- | 16,836.36 | -0.223 | -0.223 | 0.0004 | 1.36 | 0.0002 | -- | 0.0078 | 11,111.11 | -13.37 | -59.74 | -13.90 | -81.16 | -- | -- | -58,908.00 | -- | 8.78 | -- | 0.018 | -- | -- | -- | -659.00 | -- | -33.37 | -- |
| BioInvent International AB | 244.85m | -323.94m | 1.71bn | 124.00 | -- | 2.50 | -- | 6.99 | -4.91 | -4.91 | 3.72 | 10.38 | 0.2614 | -- | 4.90 | 2,147,790.00 | -34.58 | -19.38 | -38.20 | -20.57 | -- | -- | -132.30 | -189.97 | 7.31 | -- | 0.0154 | -- | -37.47 | -13.77 | -29.99 | -- | 21.19 | -- |
| Devyser Diagnostics AB | 242.80m | -25.20m | 1.81bn | 115.00 | -- | 5.29 | 1,289.47 | 7.44 | -1.52 | -1.52 | 14.66 | 20.48 | 0.5262 | 1.40 | 5.53 | 1,839,394.00 | -5.64 | -10.61 | -6.60 | -12.04 | 81.96 | 80.33 | -10.71 | -28.67 | 2.27 | -2.03 | 0.1312 | -- | 28.12 | 27.53 | -14.74 | -- | 52.54 | -- |
| Egetis Therapeutics AB (publ) | 55.40m | -333.40m | 1.97bn | 40.00 | -- | 6.44 | -- | 35.49 | -0.9376 | -0.9376 | 0.1554 | 0.7725 | 0.0945 | 45.53 | 1.93 | 1,582,857.00 | -56.85 | -36.53 | -87.92 | -41.52 | 30.14 | 81.16 | -601.62 | -558.74 | 0.7971 | -45.06 | 0.249 | -- | -19.97 | -11.00 | -5.11 | -- | -- | -- |
Data as of Feb 09 2026. Currency figures normalised to Cantargia AB's reporting currency: Swedish Krona SEK
21.59%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fj�rde AP-fondenas of 30 Jun 2025 | 24.80m | 9.98% |
| F�rsta AP-fondenas of 31 Dec 2024 | 13.00m | 5.23% |
| Handelsbanken Fonder ABas of 31 Dec 2024 | 4.66m | 1.87% |
| Swedbank Robur Fonder ABas of 31 Dec 2024 | 3.69m | 1.49% |
| American Century Investment Management, Inc.as of 08 Jan 2026 | 2.50m | 1.01% |
| SEB Funds ABas of 31 Dec 2025 | 1.62m | 0.65% |
| Storebrand Asset Management ASas of 30 Nov 2025 | 1.50m | 0.61% |
| Alphajet Fair Investors SASas of 03 Feb 2026 | 1.15m | 0.46% |
| Skandia Investment Management ABas of 28 Nov 2025 | 631.69k | 0.25% |
| Victory Capital Management, Inc. (Investment Management)as of 31 Dec 2025 | 129.72k | 0.05% |
More ▼
Data from 30 Sep 2025 - 03 Feb 2026Source: FactSet Research Systems Inc.
